Covalent Targeting of Glutamate Cysteine Ligase to Inhibit Glutathione Synthesis**
ChemBioChem · 2023-12 · 24 (23)
DOI: 10.1002/cbic.202300371 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemBioChem, online erschienen am 12.10.2023. Verfasst von Lydia H Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA, 94720, USA. Hauptthemen laut MEDLINE: Glutamate-Cysteine Ligase, Antioxidants. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Dysregulated oxidative stress plays a major role in cancer pathogenesis and some types of cancer cells are particularly vulnerable to inhibition of their cellular antioxidant capacity. Glutamate‐cysteine ligase (GCL) is the first and rate‐limiting step in the synthesis of the major cellular antioxidant glutathione (GSH). Developing a GCL inhibitor may be an attractive therapeutic strategy for certain cancer types that are particularly sensitive to oxidative stress. In this study, we reveal a cysteine‐reactive ligand, EN25, that covalently targets an allosteric cysteine C114 on GCLM, the modifier subunit of GCL, and leads to inhibition of GCL activity. This interaction also leads to reduced cellular GSH levels and impaired cell viability in ARID1A‐deficient cancer cells, which are particularly vulnerable to glutathione depletion, but not in ARID1A‐positive cancer cells. Our studies uncover a novel potential ligandable site within GCLM that can be targeted to inhibit GSH synthesis in vulnerable cancer cell types.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA, 94720, USA.
- Innovative Genomics Institute, Berkeley, CA, 94704, USA.
- Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, 94720, USA.
- Department of Chemistry, University of California, Berkeley, Berkeley, CA, 94720, USA.
- Drug Discovery Technology, Ono Pharmaceutical Company, Ltd., Osaka, 618-858, Japan.
- Research Center of Oncology, Ono Pharmaceutical Company, Ltd., Osaka, 618-8585, Japan.
ORCID-Profile: Daniel K Nomura
Förderung
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Zhang, L. H., Tang, M., Tao, X., Shao, Q., Thomas, V., Shimizu, S., Kasano, M., Ishikawa, Y., Inukai, T., & Nomura, D. K. (2023). Covalent Targeting of Glutamate Cysteine Ligase to Inhibit Glutathione Synthesis**. ChemBioChem, 24(23). https://doi.org/10.1002/cbic.202300371
Vancouver
Zhang LH, Tang M, Tao X, Shao Q, Thomas V, Shimizu S, et al. Covalent Targeting of Glutamate Cysteine Ligase to Inhibit Glutathione Synthesis**. ChemBioChem. 2023;24(23). doi:10.1002/cbic.202300371
BibTeX
@article{Zhang2023,
author = {Zhang, Lydia H and Tang, Michelle and Tao, Xavier and Shao, Qian and Thomas, Vienna and Shimizu, Saki and Kasano, Miki and Ishikawa, Yoshinori and Inukai, Takayuki and Nomura, Daniel K},
title = {Covalent Targeting of Glutamate Cysteine Ligase to Inhibit Glutathione Synthesis**},
journal = {ChemBioChem},
year = {2023},
volume = {24},
number = {23},
doi = {10.1002/cbic.202300371}
}
EUVIMED